Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2019
Probable Etoricoxib-Induced Severe Thrombocytopenia: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Recinella Guerino, De Marchi Alessandro, Pirazzoli Enrico, Bianchi Giampaolo
Аннотация
OBJECTIVE: To describe a case of likely etoricoxib-induced severe thrombocytopenia.
CLINICAL PRESENTATION AND INTERVENTION: A 32-year-old woman was referred to our hospital for disseminated petechial rash after 7 days of therapy with etoricoxib. At admission, the patient's platelet count was 3,000/mm3. At Naranjo's scale correlation between thrombocytopenia and drug was considered as "probable." With the diagnostic tests performed we did not find other causes of thrombocytopenia. Etoricoxib was discontinued. The patient was treated with intravenous immunoglobulin and corticosteroids with a complete resolution of the thrombocytopenia in a few days.
CONCLUSION: The prevalence of thrombocytopenia induced by etoricoxib should be studied as it may not be very rare.
CLINICAL PRESENTATION AND INTERVENTION: A 32-year-old woman was referred to our hospital for disseminated petechial rash after 7 days of therapy with etoricoxib. At admission, the patient's platelet count was 3,000/mm3. At Naranjo's scale correlation between thrombocytopenia and drug was considered as "probable." With the diagnostic tests performed we did not find other causes of thrombocytopenia. Etoricoxib was discontinued. The patient was treated with intravenous immunoglobulin and corticosteroids with a complete resolution of the thrombocytopenia in a few days.
CONCLUSION: The prevalence of thrombocytopenia induced by etoricoxib should be studied as it may not be very rare.